Eurartesim: Uses, Dosage & Side Effects

What Is Eurartesim and What Is It Used For?

Eurartesim is a fixed-dose combination antimalarial medication that contains two complementary active substances working through different mechanisms to kill malaria parasites. Each film-coated tablet contains 160 mg of piperaquine tetraphosphate and 20 mg of dihydroartemisinin (DHA), also known as artenimol. This dual-component approach reflects the fundamental principle behind modern antimalarial treatment: combining a fast-acting artemisinin derivative with a longer-acting partner drug to achieve rapid symptom relief, high cure rates, and reduced selection pressure for drug-resistant parasites.

Malaria remains one of the most significant global public health challenges. According to the World Health Organization’s World Malaria Report (2023), there were an estimated 249 million malaria cases and 608,000 malaria deaths worldwide in 2022, with the vast majority occurring in sub-Saharan Africa. Plasmodium falciparum is the deadliest of the five species of malaria parasites that infect humans, responsible for the overwhelming majority of malaria-related morbidity and mortality. The development of artemisinin-based combination therapies (ACTs) has been one of the most important advances in malaria control, and the WHO has recommended ACTs as the first-line treatment for uncomplicated falciparum malaria since 2006.

Dihydroartemisinin (DHA) is a potent, rapidly acting artemisinin derivative. It is actually the primary active metabolite of all artemisinin compounds (including artesunate, artemether, and artemisinin itself). DHA works by exploiting the unique biochemistry of the malaria parasite. During its blood-stage life cycle, the Plasmodium parasite ingests and degrades haemoglobin from the host’s red blood cells inside its food vacuole, releasing toxic free haem as a byproduct. Normally, the parasite detoxifies this free haem by converting it into an insoluble crystalline pigment called haemozoin. DHA contains a characteristic endoperoxide bridge – a chemical structure with two oxygen atoms linked together – that is cleaved by ferrous iron (Fe²⁺) present in the parasite’s food vacuole, generating highly reactive free radicals (reactive oxygen species). These free radicals cause massive, irreversible oxidative damage to parasite proteins, membranes, and organelles, leading to rapid parasite death. DHA reduces the parasite biomass by approximately 10,000-fold per 48-hour asexual life cycle, making it the fastest-acting of all antimalarial drugs currently available.

Piperaquine tetraphosphate is a long-acting bisquinoline antimalarial structurally related to chloroquine but with a much longer elimination half-life. Piperaquine was first synthesised in China in the 1960s and was widely used as monotherapy in China and Southeast Asia before the emergence of chloroquine-resistant P. falciparum led to its replacement. In the 2000s, piperaquine experienced a remarkable revival as a partner drug for artemisinin derivatives, precisely because its long half-life of approximately 22–33 days (depending on the population studied) provides extended post-treatment antimalarial activity. Piperaquine accumulates in the parasite’s digestive vacuole and interferes with the conversion of toxic free haem into non-toxic haemozoin, leading to a build-up of toxic haem that kills the parasite. This mechanism is similar to that of chloroquine, but piperaquine retains activity against many chloroquine-resistant strains.

The combination of these two agents in Eurartesim is strategically designed: DHA provides the rapid initial killing of the majority of parasites within the first 24–48 hours of treatment, rapidly resolving the patient’s symptoms (fever, chills, rigors). The remaining parasites – too few to cause clinical symptoms but potentially sufficient to cause recrudescence (return of the infection) if left untreated – are then eliminated by piperaquine over the following weeks. Additionally, piperaquine’s prolonged half-life provides a period of post-treatment prophylaxis, protecting the patient against new infections for several weeks after completing treatment.

Eurartesim is indicated for the treatment of uncomplicated Plasmodium falciparum malaria in adult and paediatric patients weighing 5 kg or more. It is specifically authorised for uncomplicated malaria, meaning the patient is conscious, able to take oral medication, and does not have signs of severe malaria (such as cerebral malaria, severe anaemia, acute respiratory distress, or multi-organ failure). Severe malaria is a medical emergency that requires parenteral (intravenous) treatment, typically with intravenous artesunate.

Eurartesim was authorised by the European Medicines Agency (EMA) in October 2011 under Article 58, a procedure that provides a scientific opinion for medicines intended primarily for markets outside the European Union, particularly in low- and middle-income countries where malaria is endemic. This regulatory pathway was specifically designed to support global health initiatives by leveraging the EMA’s rigorous scientific assessment standards for medicines used in developing countries. Eurartesim has since been included in the WHO Model List of Essential Medicines and is prequalified by the WHO Prequalification Programme, confirming that it meets international standards for quality, safety, and efficacy.

What Should You Know Before Taking Eurartesim?

Contraindications

Eurartesim must not be used in the following situations:

• Hypersensitivity: Known allergy to dihydroartemisinin, piperaquine, or any of the other ingredients in the tablet (hypromellose, titanium dioxide, macrogol 400, polysorbate 80, microcrystalline cellulose, croscarmellose sodium, maize starch, colloidal anhydrous silica, magnesium stearate).
• Severe malaria: Eurartesim is not indicated for the treatment of severe or complicated P. falciparum malaria. These patients require intravenous artesunate as the first-line treatment per WHO guidelines.
• Cardiac conditions: Patients with known QTc prolongation (QTc >500 ms), congenital long QT syndrome, a family history of sudden cardiac death or unexplained syncope, or clinically relevant cardiac conditions such as symptomatic bradycardia, heart failure with reduced ejection fraction, or a history of symptomatic cardiac arrhythmias should not receive Eurartesim.
• Concurrent QTc-prolonging drugs: Eurartesim must not be given concurrently with other medications known to prolong the QTc interval, including Class IA and III antiarrhythmics, certain antipsychotics, certain antibiotics (such as fluoroquinolones and macrolides), and other antimalarial drugs (such as halofantrine, chloroquine, quinine, and lumefantrine).
• Recent use of other antimalarials: Due to piperaquine’s long half-life, a second course of Eurartesim should not be given within 2 months of the first course. Concurrent use with mefloquine is also contraindicated.

Warnings and Precautions

Piperaquine is known to prolong the QTc interval in a concentration-dependent manner. In clinical trials, the mean QTcF increase was approximately 15–20 ms at peak piperaquine concentration, returning to baseline within 1–2 months after the last dose. While no cases of torsades de pointes or other life-threatening ventricular arrhythmias have been reported in clinical trials with Eurartesim, the potential risk warrants careful attention to the following precautions:

• Electrolyte imbalances: Hypokalaemia, hypomagnesaemia, and hypocalcaemia can increase the risk of QTc prolongation and should be corrected before and during treatment. These electrolyte disturbances are common in patients with acute malaria, particularly those with vomiting and diarrhoea.
• ECG monitoring: An ECG should be obtained before the second and third doses in patients with additional risk factors for QTc prolongation, and in any patient receiving a repeat course of treatment. If the QTc exceeds 500 ms, Eurartesim should be discontinued.
• Hepatic impairment: Patients with moderate to severe hepatic impairment may have increased exposure to both piperaquine and DHA. Eurartesim has not been studied in patients with severe hepatic impairment and should be used with caution in this population.
• Renal impairment: No dose adjustment is necessary for mild to moderate renal impairment. Eurartesim has not been studied in patients with severe renal impairment.

It is essential that patients do not vomit within 30 minutes of taking Eurartesim, as this may result in inadequate drug levels. If vomiting occurs within 30 minutes, the full dose should be re-administered. If vomiting occurs between 30 and 60 minutes, half the dose should be re-administered. Patients who vomit repeatedly and cannot retain oral medication should be switched to parenteral antimalarial treatment.

Pregnancy and Breastfeeding

Malaria during pregnancy carries significant risks for both the mother and fetus, including severe maternal anaemia, intrauterine growth restriction, preterm delivery, low birth weight, and maternal and fetal death. The WHO currently recommends that ACTs, including DHA-piperaquine, can be used in all trimesters of pregnancy for the treatment of uncomplicated falciparum malaria, based on accumulating safety data from observational studies and pregnancy registries. However, as with all medicines in pregnancy, the potential benefits must be weighed against the potential risks.

Animal reproductive studies with DHA have shown some evidence of embryotoxicity at very high doses, but these findings have not been replicated in human observational data at therapeutic doses. Piperaquine has not shown teratogenic effects in animal studies. Several large observational studies, including data from the WHO Malaria in Pregnancy consortium, have provided reassuring safety data for DHA-piperaquine use in the second and third trimesters. Data in the first trimester are more limited but are growing, and the WHO now supports the use of ACTs including DHA-piperaquine across all trimesters when the benefit clearly outweighs the risk.

It is not known to what extent piperaquine or DHA are excreted in human breast milk. Given the serious nature of malaria and the relatively short treatment course (3 days), breastfeeding mothers with malaria should be treated with Eurartesim as recommended, with appropriate medical supervision. The benefits of effective malaria treatment for the mother outweigh the theoretical risks to the breastfed infant.

Children and Adolescents

Eurartesim is approved for use in children weighing 5 kg or more. Given that malaria disproportionately affects young children – approximately 80% of malaria deaths occur in children under 5 years – appropriate paediatric dosing and formulation are critically important. For young children who cannot swallow tablets, the tablets may be crushed and mixed with water for immediate administration. The dosage is strictly weight-based and must be calculated using the weight-band dosing tables provided in the prescribing information.

Clinical trials have demonstrated that Eurartesim is effective and well-tolerated in the paediatric population, with cure rates comparable to those observed in adults. QTc prolongation has also been observed in children, and the same food-fasting precautions apply. Special care should be taken to ensure that children do not eat within the specified time windows around dosing.

How Does Eurartesim Interact with Other Drugs?

Unlike some monoclonal antibody therapies that have minimal drug interaction potential, Eurartesim has clinically important drug interactions that must be carefully considered before prescribing. Piperaquine is metabolised primarily by the cytochrome P450 enzyme CYP3A4, and it also acts as an inhibitor of CYP3A4 in vitro. DHA is also partially metabolised by CYP3A4 and glucuronidated by UGT1A9 and UGT2B7. These metabolic pathways create the potential for pharmacokinetic interactions with a range of commonly used medications.

The most clinically important category of drug interactions involves the additive risk of QTc prolongation. Piperaquine prolongs the QTc interval in a concentration-dependent manner, and combining it with other QTc-prolonging drugs can lead to dangerous additive effects on cardiac repolarisation. This is particularly relevant in malaria-endemic settings where patients may have been previously treated with other antimalarials, or where co-infections (such as HIV/AIDS) are common and patients may be taking multiple medications.

Major Interactions

Other Interactions of Note

Several additional interactions deserve clinical attention:

• HIV protease inhibitors (ritonavir, lopinavir): These are potent CYP3A4 inhibitors that can significantly increase piperaquine levels. In HIV-malaria co-endemic settings, careful risk-benefit assessment and ECG monitoring are essential. Some studies have reported a 2–3 fold increase in piperaquine AUC when co-administered with ritonavir-boosted protease inhibitors.
• Fluoroquinolone antibiotics (moxifloxacin, levofloxacin): These antibiotics have intrinsic QTc-prolonging potential. Co-administration with Eurartesim should be avoided where possible, or ECG monitoring should be performed if concurrent use is clinically necessary.
• Macrolide antibiotics (erythromycin, clarithromycin, azithromycin): Erythromycin and clarithromycin are both CYP3A4 inhibitors and have QTc-prolonging effects. Azithromycin has a lower risk but should still be used with caution.
• Grapefruit juice: A potent inhibitor of intestinal CYP3A4, grapefruit juice can increase piperaquine absorption. Patients should be advised to avoid grapefruit and grapefruit juice during treatment.
• St. John’s Wort (Hypericum perforatum): A strong CYP3A4 inducer that could reduce piperaquine levels and compromise treatment efficacy. Concurrent use should be avoided.

What Is the Correct Dosage of Eurartesim?

Eurartesim should always be used exactly as prescribed by your healthcare provider. The treatment consists of one oral dose taken daily for three consecutive days. Doses should be taken at the same time each day. Each dose should be swallowed with water only, without food. The strict fasting requirement (at least 3 hours after the last meal and at least 3 hours before the next meal) is not just a recommendation – it is a safety requirement to prevent dangerously elevated piperaquine blood levels that could cause QTc prolongation.

Adults

Adults weighing more than 100 kg have not been specifically studied in clinical trials. In clinical practice, the 4-tablet dose may be used, but clinicians should be aware that higher body weight may be associated with relatively lower drug exposure. Consultation with a specialist in tropical medicine is advisable in such cases.

Children (5 kg and above)

Paediatric dosing is strictly weight-based. The following dosing table should be used:

For young children who cannot swallow tablets whole, the tablets may be crushed and mixed with water for immediate administration. The crushed tablet mixture should not be stored and must be administered immediately after preparation. If the child vomits within 30 minutes of administration, the full dose should be repeated. If vomiting occurs between 30 and 60 minutes, half the dose should be re-administered.

Elderly Patients

Clinical trial data for elderly patients (over 65 years of age) are limited, as malaria predominantly affects younger populations in endemic areas. No specific dose adjustment has been established for elderly patients, but the general adult dosing recommendations should be followed. However, elderly patients are more likely to have pre-existing cardiac conditions, electrolyte abnormalities, and concomitant medications that increase the risk of QTc prolongation. ECG monitoring and careful clinical assessment are recommended in this population.

Missed Dose

If you forget to take a dose of Eurartesim, take it as soon as you remember, maintaining the fasting requirements (at least 3 hours after the last meal). Then continue with the remaining dose(s) at the usual times. It is important to complete the full 3-day treatment course even if you feel better after the first or second dose, as stopping treatment early can lead to treatment failure and promotes the development of drug-resistant parasites. Do not take a double dose to compensate for a missed dose.

Overdose

There is limited clinical experience with Eurartesim overdose. Given the known cardiac effects (QTc prolongation) of piperaquine, an overdose of Eurartesim should be treated as a medical emergency. Immediate measures should include:

• Continuous ECG monitoring for a minimum of 24–48 hours
• Correction of any electrolyte abnormalities (particularly potassium, magnesium, and calcium)
• Gastric decontamination with activated charcoal if the overdose was within the previous 1–2 hours
• Symptomatic and supportive treatment in an intensive care setting
• Monitoring for at least several days given the long half-life of piperaquine

There is no specific antidote for piperaquine or DHA. Treatment is supportive. Contact a poison control centre or emergency department immediately if overdose is suspected.

What Are the Side Effects of Eurartesim?

Like all medicines, Eurartesim can cause side effects, although not everybody gets them. It is important to note that many of the symptoms reported during clinical trials with Eurartesim – such as fever, anaemia, headache, cough, and gastrointestinal disturbances – are also common features of acute malaria itself. Distinguishing drug-related adverse effects from malaria symptoms can therefore be challenging. The side effects listed below are based on data from randomised controlled trials, post-marketing surveillance, and pharmacovigilance reports.

The most pharmacologically significant adverse effect of Eurartesim is the prolongation of the QTc interval on the electrocardiogram. In clinical trials, the maximum QTcF prolongation occurred approximately 4–5 hours after the last dose (coinciding with peak piperaquine concentrations) and averaged 15–20 ms. The QTc interval returned to baseline within 1–2 months of treatment completion. No cases of torsades de pointes, sudden cardiac death, or other life-threatening ventricular arrhythmias were reported in the clinical trial program, though the possibility cannot be excluded with widespread use.

If you experience any side effects, particularly palpitations, an irregular heartbeat, dizziness, or fainting, seek medical attention immediately, as these could indicate a cardiac arrhythmia. In clinical practice, the majority of patients tolerate the 3-day treatment course well, and most adverse effects resolve spontaneously after treatment completion.

It is also important to be aware that post-treatment haemolytic anaemia has been reported with artemisinin derivatives, particularly in patients with hyperparasitaemia (very high levels of parasites in the blood). This typically occurs 1–3 weeks after treatment and manifests as a drop in haemoglobin. Patients should have their haemoglobin checked during follow-up visits (typically at Day 7 and Day 28) to monitor for delayed haemolysis.

How Should You Store Eurartesim?

Proper storage of antimalarial medicines is particularly important in tropical and subtropical environments, where heat and humidity can degrade pharmaceutical products. Eurartesim film-coated tablets should be stored below 30°C in the original blister packaging to protect from moisture and light. Do not remove the tablets from their blister pack until immediately before use.

The shelf life of Eurartesim, when stored under the recommended conditions, is 30 months (2.5 years) from the date of manufacture. Do not use this medicine after the expiry date printed on the carton and blister pack. The expiry date refers to the last day of that month.

Keep this medicine out of the sight and reach of children. Malaria is most common in settings where young children are present, and accidental ingestion of antimalarial medicines can be dangerous, particularly given the cardiac effects of piperaquine. If a child accidentally swallows Eurartesim tablets, seek immediate medical attention and bring the medicine packaging to the hospital.

Do not dispose of Eurartesim in household waste or wastewater. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help to protect the environment and reduce the risk of pharmaceutical contamination of water sources.

What Does Eurartesim Contain?

Each Eurartesim film-coated tablet contains the following:

Active Substances

• Piperaquine tetraphosphate: 160 mg (equivalent to approximately 128 mg piperaquine base). Piperaquine is a bisquinoline compound that acts as a long-acting blood schizonticide, providing sustained antimalarial activity over approximately 22–33 days due to its very long elimination half-life.
• Dihydroartemisinin (DHA / artenimol): 20 mg. DHA is the most potent artemisinin derivative and the active metabolite of all artemisinin-class drugs. It provides rapid initial parasite killing and has a short half-life of approximately 1 hour.

Inactive Ingredients (Excipients)

The tablet core contains:

• Microcrystalline cellulose (filler/binder)
• Croscarmellose sodium (disintegrant)
• Maize starch (filler/binder)
• Colloidal anhydrous silica (glidant)
• Magnesium stearate (lubricant)

The film coating contains:

• Hypromellose (film-forming agent)
• Titanium dioxide E171 (opacifier/whitening agent)
• Macrogol 400 (plasticiser)
• Polysorbate 80 (emulsifier)

Eurartesim tablets are white, oblong, film-coated tablets. They are packaged in aluminium/aluminium blisters within a cardboard carton. The number of tablets per carton varies by market but is designed to provide a complete treatment course based on the patient’s weight band.

The tablets do not contain gluten, lactose, or any animal-derived ingredients. This information may be relevant for patients with specific dietary requirements or religious considerations.